Locations:
March 2, 2022/Neurosciences/Podcast

Neurostimulation for Treatment of Obstructive Sleep Apnea (Podcast)

An in-depth look at this alternative for patients who cannot tolerate PAP therapy

While there are comprehensive treatment options for obstructive sleep apnea (OSA), the disorder is underrecognized and underdiagnosed, says Jessica Vensel Rundo, MD, MS, Director of the Sleep Neuromodulation Program in Cleveland Clinic’s Sleep Disorders Center.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“About 25% to 50% of males and 10% to 25% of females have some degree of obstructive sleep apnea,” says Dr. Vensel Rundo. “That translates to many millions of Americans.”

In 2014, a new category of surgical therapy became available to help this population when the FDA approved the first neurostimulation device to treat OSA. In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Vensel Rundo discusses OSA and hypoglossal nerve stimulation, providing insight on the following:

  • Positive airway pressure (PAP) therapy as the first line of treatment for OSA
  • Screening criteria and ideal candidates for airway neurostimulation
  • Implantation and function of the transcutaneous electrical stimulator
  • Patient outcomes following neurostimulation
  • Potential future devices, including a bilateral hypoglossal nerve stimulator and a continuous negative expiratory pressure device

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

This activity has been approved for AMA PRA Category 1 Credit™. After listening to the podcast, you can claim your credit here.

Excerpt from the episode

Podcast host Glen Stevens, DO, PhD: Would you recommend that anybody who is thinking about airway neurostimulation see a sleep specialist, or can they go to their general neurologist for this?

Dr. Vensel Rundo: I think it usually is most helpful if they can be referred to a sleep specialist, just to discuss in more detail what their issues are with PAP therapy and what other potential options there might be in addition to hypoglossal nerve stimulation.

Advertisement

Also, we see a number of patients who are intolerant to PAP therapy or just struggle with whatever their treatment option is for sleep apnea. Other patients may also struggle because they have additional sleep disorders like insomnia, restless legs syndrome or circadian rhythm disorders. In these cases, a sleep specialist is best equipped to assess why these patients may have difficulties adhering to their current treatment option and to determine whether other sleep disorders may be contributing to these difficulties.

Advertisement

Related Articles

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650×450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

illustration of a bright clinical room with clinicians inside

Inside Our Neurological Institute’s Next-Generation Advanced Therapeutics Space

Combining customized care, research capabilities and flexibility for the future

stylized illustration of human brain made up of cogs and wheels
October 9, 2026/Neurosciences/Brain Health

How Alzheimer’s Disease Studies Need to Evolve in the Targeted Therapy Era

Leading investigators outline a new roadmap for clinical trials and observational research

Older man tending to houseplants

TEMPO-2 Trial Shows Promise for Tavapadon in Newly Diagnosed Parkinson’s Disease

The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.

illustration of human brain with swirls of activity inside it
September 23, 2026/Neurosciences/Brain Health

Cleveland ADRC Renewal Boosts Research Into Alzheimer’s Progression

5-year funding award supports cohort expansion and deep phenotyping of AD and related dementias

young man meditating on a sofa
September 21, 2026/Neurosciences/Epilepsy

Lifestyle Interventions Show Promise as Adjunctive Epilepsy Management

Highest response rates seen with stress-lowering techniques like yoga, meditation and mindfulness

Ad